PDS Biotechnology (NASDAQ:PDSB – Free Report) had its price objective cut by Oppenheimer from $23.00 to $20.00 in a research report released on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock.
A number of other equities analysts also recently issued reports on PDSB. B. Riley reaffirmed a buy rating on shares of PDS Biotechnology in a report on Friday, October 6th. StockNews.com upgraded PDS Biotechnology to a sell rating in a research report on Wednesday, October 25th. Finally, HC Wainwright reiterated a buy rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Wednesday, October 11th.
PDS Biotechnology Stock Performance
Institutional Trading of PDS Biotechnology
A number of large investors have recently made changes to their positions in PDSB. Oppenheimer & Co. Inc. boosted its stake in shares of PDS Biotechnology by 78.6% during the first quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the company’s stock valued at $155,000 after acquiring an additional 11,000 shares during the last quarter. BlackRock Inc. boosted its stake in PDS Biotechnology by 1.0% in the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock worth $2,697,000 after buying an additional 4,199 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in PDS Biotechnology by 99.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 69,628 shares of the company’s stock worth $431,000 after buying an additional 34,797 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of PDS Biotechnology by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 1,093,885 shares of the company’s stock worth $6,771,000 after purchasing an additional 79,025 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of PDS Biotechnology by 49.5% in the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock worth $4,117,000 after purchasing an additional 220,300 shares during the period. Institutional investors and hedge funds own 25.78% of the company’s stock.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
- Five stocks we like better than PDS Biotechnology
- How to Invest and Trade Chinese Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Find and Profitably Trade Stocks at 52-Week Lows
- MarketBeat Week in Review – 11/13 – 11/17
- What is Forex and How Does it Work?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.